**PHE publications gateway number: 2015765**

## PATIENT GROUP DIRECTION (PGD)

Administration of measles, mumps and rubella (MMR) vaccine to individuals from 1 year of age for routine immunisation, or from 6 months of age if early protection is required, in accordance with the national immunisation programme and PHE guidelines on post-exposure prophylaxis for measles.

This PGD is for the administration of measles, mumps and rubella (MMR) vaccine by registered healthcare practitioners identified in Section 3, subject to any limitations to authorisation detailed in Section 2.

Reference no: MMR Vaccine PGD

Version no:v02.00

Valid from: 1 March 2018

Review date: 1 August 2019

Expiry date: 29 February 2020

**Public Health England has developed this PGD template to facilitate delivery of immunisations in the NHS in line with national recommendations.**

Those using this PGD must ensure that it is organisationally authorised and signed in Section 2 by an appropriate authorising person, relating to the class of person by whom the product is to be supplied, in accordance with Human Medicines Regulations 2012 (HMR2012)[[1]](#footnote-2). **THE PGD IS NOT LEGAL OR VALID WITHOUT SIGNED AUTHORISATION IN ACCORDANCE WITH** [**HMR2012 SCHEDULE 16 Part 2**](http://www.legislation.gov.uk/uksi/2012/1916/schedule/16/part/2/made)**.**

Authorising organisations must not alter or amend the clinical content of this document (sections 4, 5 and 6); such action will invalidate the clinical sign-off with which it is provided. In addition authorising organisations must not alter section 3 ‘Characteristics of staff’. Only sections 2 and 7 can be amended.

Operation of this PGD is the responsibility of commissioners and service providers.

**INDIVIDUAL PRACTITIONERS MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE WORKING ACCORDING TO IT.**

Practitioners and organisations must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date. Current versions of PHE PGD templates for local authorisation can be found from:

<https://www.gov.uk/government/collections/immunisation>

Any concerns regarding the content of this PGD should be addressed to:

[Immunisation@phe.gov.uk](mailto:Immunisation@phe.gov.uk)

# **Change history**

|  |  |  |
| --- | --- | --- |
| **Version number** | **Change details** | **Date** |
| V01.00 | New PHE PGD template | 3 March 2016 |
| V02.00 | PHE MMR PGD amended to:   * include additional healthcare practitioners (pharmacists, paramedics, physiotherapists) in Section 3 * amend age from 12 months to 1 year * move neurological conditions from exclusions to cautions to align with “The Green Book” Chapter 6 guidance * revise cautions * clarify dose and frequency of administration section * add paragraph on patient consent to the off-label section * reference the protocol for ordering, storage and handling of vaccines * refer to vaccine incident guidelines * include rewording, layout and formatting changes for clarity and consistency with other PHE PGD templates | 26 January 2018 |

1. **PGD template development**

This PGD template has been developed by the following health professionals on behalf of Public Health England:

|  |  |  |  |
| --- | --- | --- | --- |
| **Developed by:** | **Name** | **Signature** | **Date** |
| Pharmacist (Lead Author) | Elizabeth Graham  Lead Pharmacist Immunisation Services, PHE | C:\Users\beth.graham\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Word\Signature 1.jpeg | 31/01/2018 |
| Doctor | Mary Ramsay  Consultant Epidemiologist and Head of Immunisation, Hepatitis & Blood Safety Department, PHE |  | 31/01/2018 |
| Registered Nurse (Chair of Expert Panel) | David Green  Nurse Consultant – Immunisations, PHE |  | 31/01/2018 |

This PGD template has been peer reviewed by the PHE Immunisations PGD Expert Panel in accordance with PHE PGD Policy. It has been ratified by the PHE Medicines Management Group and the PHE Quality and Clinical Governance Delivery Board.

**Expert Panel**

|  |  |
| --- | --- |
| **Name** | **Designation** |
| Ed Gardner | Advanced Paramedic Practitioner/Emergency Care Practitioner, Medicines Manager, Proactive Care Lead |
| Jacqueline Lamberty | Lead Pharmacist Medicines Management Services, Public Health England |
| Vanessa MacGregor | Consultant in Communicable Disease Control, Public Health England, East Midlands Health Protection Team |
| Alison Mackenzie | Consultant in Public Health Medicine, Screening and Immunisation Lead, Public Health England / NHS England South (South West) |
| Gill Marsh | Senior Screening and Immunisation Manager Public Health England / NHS England Lancashire and South Cumbria |
| Lesley McFarlane | Screening and Immunisation Co-ordinator (SIC) NHS England Leicestershire, Lincolnshire and Northamptonshire |
| Sally Millership | Consultant in Communicable Disease Control, Public Health England, East of England Health Protection Team |
| Lisa Rees | Medicines Management Pharmacist, Bristol Clinical Commissioning Group |
| Vanessa Saliba | Consultant Epidemiologist, Public Health England |
| Tushar Shah | Pharmacy Advisor, NHS England London Region |
| Kelly Stoker | Senior Health Protection Nurse, North East Health Protection Team, Public Health England Centre North East |
| Sharon Webb | Programme Manager - IDPS , NHS Screening Programmes, Public Health England (Midwife) |

1. **Organisational authorisations**

The PGD is not legally valid until it has had the relevant organisational authorisation.

It is the responsibility of the organisation that has legal authority to authorise the PGD, to ensure that all legal and governance requirements are met. The authorising body accepts governance responsibility for the appropriate use of the PGD.

INSERT AUTHORISING BODY NAME authorises this PGD for use by the services or providers listed below:

|  |
| --- |
| Authorised for use by the following organisations and/or services |
| eg All NHS England commissioned immunisation services or NHS Trust providing immunisation services. |
| Limitations to authorisation |
| eg Any local limitations the authorising organisation feels they need to apply in-line with the way services are commissioned locally. This organisation does not authorise the use of this PGD by …. |

|  |  |  |  |
| --- | --- | --- | --- |
| Organisational approval (legal requirement) | | | |
| Role | Name | Sign | Date |
| Complete eg NHS England Governance Lead, Medical Director |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| Additional signatories according to locally agreed policy | | | |
| Role | Name | Sign | Date |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

Local enquiries regarding the use of this PGD may be directed to…………….

Section 7 provides a practitioner authorisation sheet. Individual practitioners must be authorised by name to work to this PGD. Alternative practitioner authorisation sheets may be used where appropriate in accordance with local policy but this should be an individual agreement or a multiple practitioner authorisation sheet as included at the end of this PGD.

#### Characteristics of staff

|  |  |
| --- | --- |
| **Qualifications and professional registration** | Registered professional with one of the following bodies:   * nurses and midwives currently registered with the Nursing and Midwifery Council (NMC) * pharmacists currently registered with the General Pharmaceutical Council (GPhC) (Note: This PGD is not relevant to privately provided community pharmacy services) * paramedics and physiotherapists currently registered with Health and Care Professions Council (HCPC)   The practitioners above must also fulfil the [Additional requirements](#StaffAdditionalRequirements) detailed below.  Check [Section 2 Limitations to authorisation](#LimitationsToAuthorisation) to confirm whether all practitioners listed above have organisational authorisation to work under this PGD. |
| **Additional requirements** | Additionally practitioners:   * must be authorised by name as an approved practitioner under the current terms of this PGD before working to it * must have undertaken appropriate training for working under PGDs for supply/administration of medicines * must be competent in the use of PGDs (see [NICE Competency framework](https://www.nice.org.uk/guidance/mpg2/resources) for health professionals using PGDs) * must be familiar with the vaccine product and alert to changes in the Summary of Product Characteristics (SPC), Immunisation Against Infectious Disease (“[The Green Book](https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book)”), and national and local immunisation programmes * must have undertaken training appropriate to this PGD as required by local policy and in line with the [National Minimum Standards for Immunisation Training](https://www.gov.uk/government/publications/immunisation-training-national-minimum-standards) * must be competent to undertake immunisation and to discuss issues related to immunisation * must be competent in the handling and storage of vaccines, and management of the “cold chain” * must be competent in the recognition and management of anaphylaxis * must have access to the PGD and associated online resources * should fulfil any additional requirements defined by local policy   **THE PRACTITIONER MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE WORKING ACCORDING TO IT.** |
| **Continued training requirements** | Practitioners must ensure they are up to date with relevant issues and clinical skills relating to immunisation and management of anaphylaxis, with evidence of appropriate Continued Professional Development (CPD).  Practitioners should be constantly alert to any subsequent recommendations from Public Health England and/or NHS England and other sources of medicines information.  Note: The most current national recommendations should be followed but a Patient Specific Direction (PSD) may be required to administer the vaccine in line with updated recommendations that are outside the criteria specified in this PGD. |

1. **Clinical condition or situation to which this PGD applies**

|  |  |
| --- | --- |
| **Clinical condition or situation to which this PGD applies** | Indicated for the active immunisation of individuals from 1 year of age for routine immunisation, or from 6 months of age if early protection is required, for the prevention of measles, mumps and/or rubella in accordance with the national immunisation programme, [PHE Guidelines on post-exposure prophylaxis for measles](https://www.gov.uk/government/publications/measles-post-exposure-prophylaxis) and recommendations given in [Chapter 21](https://www.gov.uk/government/publications/measles-the-green-book-chapter-21), [Chapter 23](https://www.gov.uk/government/publications/mumps-the-green-book-chapter-23) and [Chapter 28](https://www.gov.uk/government/publications/rubella-the-green-book-chapter-28) of Immunisation Against Infectious Disease: “The Green Book”. |
| **Criteria for inclusion** | Individuals who:   * are aged 1 year or older (ie have attained their first birthday) and are incompletely or un-immunised with MMR vaccine or of unknown vaccination status\* * are between 6 months and 1 year of age and early protection is considered necessary eg due to travel or outbreak * are aged 6 months and over and vaccination is indicated for measles post-exposure prophylaxis in accordance with PHE recommendations   \*See [Special considerations / additional information](#SpecConsidAdditionalInfo) section for further detail on patient groups at particular risk from measles, mumps or rubella infection and opportunities to check immunisation status and vaccinate as appropriate. |
| **Criteria for exclusion[[2]](#footnote-3)** | Individuals for whom no valid consent has been received.  Individuals who:   * are less than 1 year of age (ie have not yet attained their first birthday) unless early protection is required * are less than 6 months of age * have had a confirmed anaphylactic reaction to a previous dose of any measles, mumps or rubella containing vaccine or to any components of the vaccine, these may include neomycin or gelatin (refer to relevant SPC) * are known to be pregnant * have a primary or acquired immunodeficiency state(see “The Green Book” [Chapter 6](https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6) for more detail).. * are on current or recent high dose immunosuppressive or biological therapy (see “The Green Book” [Chapter 6](https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6) for more detail) * have received varicella, zoster or yellow fever vaccine in the preceding 4 weeks, unless protection against measles is required rapidly (see [Drug Interactions](#DrugInteractions)) * have received blood products, such as immunoglobulins, in the preceding 3 months, unless protection against measles is required rapidly (see [Drug Interactions](#DrugInteractions)) * are awaiting reading of a tuberculin (Mantoux) skin test, unless protection against measles is required rapidly (see [Drug Interactions](#DrugInteractions)) * are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation) |
| **Cautions including any relevant action to be taken** | Individuals who are immunosuppressed or have HIV infection who are not contraindicated this live vaccine (see “The Green Book” [Chapter 6](https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6) and seek specialist advice as appropriate), may not make a full antibody response and revaccination on cessation of treatment/recovery may be required. This should be discussed with the appropriate/relevant specialist.  If idiopathic thrombocytopaenic purpura (ITP) has occurred within six weeks of the first dose of MMR, then blood should be taken and tested for measles, mumps and rubella antibodies before a second dose is given. Serum should be sent to PHE National Infection Service Virus Reference Department (Colindale), which offers free, specialised serological testing for such children. If the results suggest incomplete immunity against measles, mumps or rubella, then a second dose of MMR is recommended.  The presence of a neurological condition is not a contraindication to immunisation but if there is evidence of current neurological deterioration, deferral of vaccination may be considered, to avoid incorrect attribution of any change in the underlying condition. The risk of such deferral should be balanced against the risk of the preventable infection, and vaccination should be promptly given once the diagnosis and/or the expected course of the condition become clear.  Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints. |
| **Action to be taken if the patient is excluded**  Continued over page  **Action to be taken if the patient is excluded**  continued | If aged less than 1 year and early protection is not required, advise to return for routine immunisation on or after the childs first birthday and give an appropriate appointment where possible.  If aged less than 6 months, MMR vaccine is not indicated. Seek advice regarding post-exposure prophylaxis as immunoglobulin may be indicated – a PSD will be required.  Individuals who have had a confirmed anaphylactic reaction to a previous dose of MMR vaccine or any components of the vaccine should be referred to a clinician for specialist advice and appropriate management.  Individuals who are pregnant should be advised to avoid contact with known or suspected cases of measles, mumps and rubella infection and report any rash illness or contact with rash illness to their GP and/or midwife. Women who are lacking two documented doses of MMR should be immunised after their pregnancy, at the earliest opportunity and before any further pregnancies. Note: MMR can be given to breast-feeding mothers without any risk to their baby.  Individuals who have a primary or acquired immunodeficiency state or who are currently, or were recently, on high dose immunosuppressive or biological therapy (see [Chapter 6](https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6)): consult appropriate specialist regarding the individual’s immune status and suitability for receiving live MMR vaccine. Administration may be indicated in some cases – a PSD will be required.  Individuals who have been immunised against varicella, zoster or yellow fever within the last 4 weeks, or received blood products in the preceding 3 months, and do not require rapid protection against MMR, defer immunisation until appropriate interval (see [Dose and Frequency of Administration](#DoseAndFrequencyOfAdministration) and [Drug Interactions](#DrugInteractions) section).  Individuals who are awaiting reading of a tuberculin (Mantoux) test, should delay MMR vaccination until the skin test has been read unless protection against measles is required urgently.  Individuals suffering acute severe febrile illness should postpone immunisation until they have recovered; immunisers should advise when the individual can be vaccinated and ensure another appointment is arranged.  Seek appropriate advice from the local Screening and Immunisation Team, local Health Protection Team or the individual’s clinician as required.  The risk to the individual of not being immunised must be taken into account.  Document the reason for exclusion and any action taken in the individual’s clinical records.  In a GP practice setting, inform or refer to the GP or a prescriber as appropriate. |
| **Action to be taken if the patient or carer declines treatment** | Informed consent, from the individual or a person legally able to act on the person’s behalf, must be obtained for each administration.  Advise the individual/parent/carer about the protective effects of the vaccine, the risks of infection and potential complications.  Document advice given and the decision reached.  In a GP practice setting, inform or refer to the GP as appropriate. |
| **Arrangements for referral for medical advice** | As per local policy |

1. **Description of treatment**

|  |  |
| --- | --- |
| **Name, strength & formulation of drug** | Measles, mumps and rubella vaccine (live)  Eg:   * Priorix®, powder and solvent for solution for injection in a pre-filled syringe * MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe |
| **Legal category** | Prescription only medicine (POM) |
| **Black triangle▼** | No |
| **Off-label use** | Administration to infants between 6 months and 9 months of age is off-label in accordance with PHE [guidance for measles post exposure prophylaxis](https://www.gov.uk/government/publications/measles-post-exposure-prophylaxis) and recommendations given in [Chapter 21](https://www.gov.uk/government/publications/measles-the-green-book-chapter-21), [Chapter 23](https://www.gov.uk/government/publications/mumps-the-green-book-chapter-23) and [Chapter 28](https://www.gov.uk/government/publications/rubella-the-green-book-chapter-28) of Immunisation Against Infectious Disease: “The Green Book”.  Vaccine should be stored according to the conditions detailed in the [Storage section](#Storage) below. However, in the event of an inadvertent or unavoidable deviation of these conditions refer to [PHE Vaccine Incident Guidance](https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors). Where vaccine is assessed in accordance with these guidelines as appropriate for continued use this would constitute off-label administration under this PGD.  Where a vaccine is recommended off-label consider, as part of the consent process, informing the individual/parent/carer that the vaccine is being offered in accordance with national guidance but that this is outside the product licence. |
| **Route / method of administration** | The vaccine must be reconstituted in accordance with the manufacturer’s instructions prior to administration.  Administer by intramuscular injection. The deltoid region of the upper arm may be used in individuals over one year of age. The anterolateral aspect of the thigh is the preferred site for infants under one year old.  When administering at the same time as other vaccines care should be taken to ensure that the appropriate route of injection is used for all the vaccinations. The vaccines should be given at separate sites, preferably in different limbs. If given in the same limb, they should be given at least 2.5cm apart. The site at which each vaccine was given should be noted in the individual’s records.  For individuals with a bleeding disorder, vaccines normally given by an intramuscular route should be given by deep subcutaneous injection to reduce the risk of bleeding (see “The Green Book” [Chapter 4](https://www.gov.uk/government/publications/immunisation-procedures-the-green-book-chapter-4)).  The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.  The vaccine’s SPC provides further guidance on administration and is available from the electronic Medicines Compendium website:  [www.medicines.org.uk](http://www.medicines.org.uk) |
| **Dose and frequency of administration** | Single 0.5ml dose per administration.  **Routine childhood immunisation schedule**  A total of two doses of 0.5ml provided at the recommended interval (see below):   * the first dose should routinely be given at 1 year of age (on or after the first birthday) * the second dose is routinely scheduled before school entry at three years four months of age   Note: The second dose can be given at any time from three months after the first dose to complete the course. Allowing three months between doses is likely to maximise the response rate, particularly in young children under the age of 18 months where maternal antibodies may reduce the response to vaccination. Where protection against measles is urgently required, the second dose can be given one month after the first (see [Early vaccination](#EarlyVaccination) paragraphs below).  **Incomplete immunisation history**  Individuals from 1 year of age who have not received an MMR vaccine should receive a dose and be brought up to date at the earliest opportunity.  An individual who has already received one dose of MMR should receive a second dose according to the routine schedule or at least 1 month after the first dose (when aged 18 months or over) to ensure that they are protected.  See the [vaccination of individuals with uncertain or incomplete immunisation status](https://www.gov.uk/government/publications/vaccination-of-individuals-with-uncertain-or-incomplete-immunisation-status) flow chart.  **Early vaccination due to travel, outbreak or contact with a probable or confirmed case of measles**  The MMR vaccine can be given from 6 months of age when early protection is required.  The response to MMR in infants is sub-optimal where the vaccine has been given before 1 year of age. If a dose of MMR is given before the first birthday, then this dose should be ignored. Two further doses of MMR should be given at the recommended ages in accordance with the routine schedule (ie at 1 year of age and a pre-school booster).  Children who are travelling to epidemic or endemic areas, or who are a contact with a probable or confirmed case of measles, who have received one dose of MMR at the routine age should have the second dose brought forward to at least one month after the first. If the child is under 18 months of age and the second dose is given within three months of the first dose, then the routine pre-school dose (a third dose) should be given in order to ensure full protection. |
| **Duration of treatment** | Two doses of 0.5ml at the recommended interval (see [Dose and Frequency of Administration](#DoseAndFrequencyOfAdministration) above).  Doses that are administered earlier than the routine schedule, given within 4 weeks of previous yellow fever, varicella or zoster vaccine, or within 3 months of receiving blood products (see [Drug Interactions](#DrugInteractions) section), may need to be repeated (see [Dose and Frequency of Administration](#DoseAndFrequencyOfAdministration) section above). |
| **Quantity to be supplied / administered** | Single 0.5ml dose per administration. |
| **Supplies** | Centrally purchased vaccines for the national immunisation programme for the NHS can only be ordered via ImmForm. Vaccines for use for the national immunisation programme are provided free of charge. National stock may also be used to for catch-up vaccination of individuals of any age.  Protocols for the ordering, storage and handling of vaccines should be followed to prevent vaccine wastage (see [protocol for ordering storage and handling of vaccines](https://www.gov.uk/government/publications/protocol-for-ordering-storing-and-handling-vaccines) and Green Book [Chapter 3](https://www.gov.uk/government/publications/storage-distribution-and-disposal-of-vaccines-the-green-book-chapter-3)). |
| **Storage** | Store between +2°C to +8°C.  Store in original packaging in order to protect from light.  Do not freeze.  After reconstitution, the vaccine should be administered promptly or stored between +2°C to +8°C and used within 8 hours of reconstitution. If not used after this time it should be discarded.  In the event of an inadvertent or unavoidable deviation of these conditions, vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued off-label use or appropriate disposal. Refer to [PHE Vaccine Incident Guidance](https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors). |
| **Disposal** | Equipment used for immunisation, including used vials, ampoules, or discharged vaccines in a syringe or applicator, should be disposed of at the end of a session by sealing in a UN-approved puncture-resistant ‘sharps’ box, according to local authority regulations and guidance in the [technical memorandum 07-01](https://www.gov.uk/government/publications/guidance-on-the-safe-management-of-healthcare-waste): Safe management of healthcare waste (Department of Health, 2013). |
| **Drug interactions**  Continued over page  **Drug interactions**  (continued) | Immunological response may be diminished in those receiving immunosuppressive treatment.  May be given at the same time as inactivated vaccines or at any interval before or after.  MMR may attenuate the response to other live vaccines. [The revised recommendations for the administration of more than one live vaccine](https://www.gov.uk/government/publications/revised-recommendations-for-administering-more-than-1-live-vaccine) should be followed. These are summarised in [Table 1](#Table1) below.  Where protection against measles is required rapidly then the vaccines should be given at any interval. As the response may be suboptimal if given within 4 weeks of previous yellow fever, varicella or zoster vaccine, an additional dose of MMR should be considered.  If protection against measles is urgently required, then the benefit of protection from the vaccine outweighs the potential interference with a tuberculin test. In this circumstance, the individual interpreting the negative tuberculin test should be made aware of the recent MMR vaccination when considering how to manage that individual.  When MMR is given within three months of receiving blood products, such as immunoglobulin, the response to the measles component may be reduced. This is because such blood products may contain significant levels of measles-specific antibody, which could then prevent vaccine virus replication. Where possible, MMR should be given at least three weeks before or deferred until three months after receipt of such products. If immediate measles protection is required in someone who has recently received a blood product, MMR vaccine should still be given. To confer longer-term protection, MMR should be repeated after three months.   |  |  | | --- | --- | | Table 1: Recommendations for giving more than one live attenuated vaccine in current use in the UK | | | **Vaccine combinations** | **Recommendations** | | Yellow Fever and MMR | A four week minimum interval period should be observed between the administration of these two vaccines. Yellow Fever and MMR should **not** be administered on the same day. | | Varicella (and zoster) vaccine and MMR | If these vaccines are not administered on the same day, then a four week minimum interval should be observed between vaccines. | | Tuberculin skin testing (Mantoux) and MMR | If a tuberculin skin test has already been initiated, then MMR should be delayed until the skin test has been read unless protection against measles is required urgently. If a child has had a recent MMR, and requires a tuberculin test, then a four week interval should be observed. | | All currently used live vaccines[[3]](#footnote-4) and tuberculin (Mantoux) skin testing. | Apart from those combinations listed above, these live vaccines can be administered at any time before or after each other. |   A detailed list of drug interactions is available in the SPC, which is available from the electronic Medicines Compendium website: [www.medicines.org.uk](http://www.medicines.org.uk) |
| **Identification & management of adverse reactions**  Continued over page  **Identification & management of adverse reactions**  (continued) | The most common adverse reactions are fever and injection site reactions including pain, swelling and erythema.  Malaise, fever and/or a rash may occur, most commonly about a week after immunisation, and last about two to three days. In studies parotid swelling occurred in about 1% of children of all ages up to four years, usually in the third week.  Events due to the measles component occur six to eleven days after vaccination. Events due to the mumps and rubella components usually occur two to three weeks after vaccination but may occur up to six weeks after vaccination. Individuals with vaccine-associated symptoms are not infectious to others.  Adverse reactions are considerably less common after a second dose of MMR vaccine than after the first dose.  Hypersensitivity reactions and anaphylaxis can occur but are very rare.  **Rare and more serious events**  Febrile seizures are the most commonly reported neurological event following measles immunisation. Seizures occur during the sixth to eleventh day in 1 in 1000 children vaccinated with MMR.  Arthropathy (arthralgia or arthritis) has also been reported to occur rarely after MMR immunisation, probably due to the rubella component. If it is caused by the vaccine, it should occur between 14 and 21 days after immunisation. Where it occurs at other times, it is highly unlikely to have been caused by vaccination.  ITP has occurred rarely following MMR vaccination, usually within six weeks of the first dose and resolves spontaneously. The risk of developing ITP after MMR vaccine is much less than the risk of developing it after infection with wild measles or rubella virus (see Cautions).  Further details on adverse reactions following MMR vaccine can be found in “The Green Book” [Chapter 21](https://www.gov.uk/government/publications/measles-the-green-book-chapter-21), [Chapter 23](https://www.gov.uk/government/publications/mumps-the-green-book-chapter-23) and [Chapter 28](https://www.gov.uk/government/publications/rubella-the-green-book-chapter-28).  A detailed list of adverse reactions is available in the vaccine’s SPC, which is available from the electronic Medicines Compendium website:  [www.medicines.org.uk](http://www.medicines.org.uk) |
| **Reporting procedure of adverse reactions** | Healthcare professionals and individuals/parents/carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on: <http://yellowcard.mhra.gov.uk>  Any adverse reaction to a vaccine should be documented in the individual’s record and the individual’s GP should be informed. |
| **Written information to be given to patient or carer** | Offer marketing authorisation holder's patient information leaflet (PIL) provided with the vaccine.  Immunisation promotional material may be provided as appropriate:   * [Immunisations at 1 year of age](https://www.gov.uk/government/publications/immunisations-between-12-and-13-months-of-age) * [Pre-school immunisations: guide to vaccinations (2 to 5 years)](https://www.gov.uk/government/publications/pre-school-vaccinations-a-guide-to-vaccinations-from-2-to-5-years)   Available from: [www.gov.uk/government/collections/immunisation](http://www.gov.uk/government/collections/immunisation) |
| **Patient advice / follow up treatment** | Inform the individual/parent/carer of possible side effects and their management.  Advise about likely timing of any fever and management of a fever.  Advise where relevant that pregnancy should be avoided for 1 month post vaccination.  The individual/parent/carer should be advised to seek medical advice in the event of an adverse reaction.  When administration is postponed advise the individual/parent/carer when to return for vaccination. |
| **Special considerations / additional information**  Continued over page  **Special considerations / additional information**  (continued) | Ensure there is immediate access to adrenaline (epinephrine) 1 in 1000 injection and access to a telephone at the time of vaccination.  Recent data suggest that anaphylactic reactions to MMR vaccine are not associated with hypersensitivity to egg antigens. All children with egg allergy should receive the MMR vaccination as a routine procedure in primary care.  MMRVaxPRO® (Sanofi Pasteur MSD) contains porcine gelatine. Priorix® (GSK) does NOT contain porcine gelatine and can be offered as an alternative to MMRVaxPRO®. Health professionals should be aware to order Priorix® when running clinics for relevant communities (see [Vaccines and porcine gelatine](https://www.gov.uk/government/publications/vaccines-and-porcine-gelatine) leaflet).  MMR vaccine is recommended when protection against measles, mumps and/or rubella is required. MMR vaccine can be given irrespective of a history of measles, mumps or rubella infection or vaccination. There are no ill effects from vaccinating those who are already immune. If there is doubt about an individual’s MMR immune status, MMR vaccine should still be given.  Children with chronic conditions such as cystic fibrosis, congenital heart or kidney disease, failure to thrive or Down’s syndrome are at particular risk from measles infection and should be immunised with MMR vaccine.  MMR vaccine can be provided to children and adults of any age over 6 months using this PGD. The decision on when to vaccinate adults needs to take into consideration the past vaccination history, the likelihood of an individual remaining susceptible and the future risk of exposure and disease see “The Green Book” [Chapter 21](https://www.gov.uk/government/publications/measles-the-green-book-chapter-21), [Chapter 23](https://www.gov.uk/government/publications/mumps-the-green-book-chapter-23) and [Chapter 28](https://www.gov.uk/government/publications/rubella-the-green-book-chapter-28).  Entry into college, university or other higher education institutions, prison or military service provides an opportunity to check an individual’s immunisation history. Those who have not received two doses of MMR should be offered appropriate MMR immunisation.  Pre-conceptual care, antenatal and post-natal checks provide an opportunity to assess MMR status. Individuals who have not received two doses of MMR at an appropriate interval should be offered pre- or post-natal MMR immunisation. Pregnancy should be avoided for at least 1 month following vaccination.  Children and adults coming from abroad may not have been immunised against measles, mumps and rubella. Unless there is a reliable history of appropriate immunisation, individuals should be assumed to be unimmunised.  **Post Exposure**  Antibody responses to the rubella and mumps components of MMR vaccine do not develop soon enough to provide effective prophylaxis after exposure to these infections. However, as vaccine-induced measles antibody develops more rapidly than that following natural infection, MMR vaccine should be used to protect susceptible contacts from suspected measles. To be effective against this exposure, vaccine must be administered very promptly, ideally within three days.  Even where it is too late to provide effective post-exposure prophylaxis with MMR, the vaccine can provide protection against future exposure to all three infections. Therefore, contact with suspected measles, mumps or rubella provides a good opportunity to offer MMR vaccine to previously unvaccinated individuals.  If the individual is already incubating measles, mumps or rubella, MMR vaccination will not exacerbate the symptoms. In these circumstances, individuals should be advised that a measles, mumps or rubella-like illness occurring shortly after vaccination is likely to be due to natural infection.  Immunoglobulin may be indicated for contacts of measles who are infants, immunosuppressed or pregnant. Provision of immunoglobulin is not covered by this PGD. |
| **Records** | Record:   * that valid informed consent was given * name of individual, address, date of birth and GP with whom the individual is registered * name of immuniser * name and brand of vaccine * date of administration * dose, form and route of administration of vaccine * quantity administered * batch number and expiry date * anatomical site of vaccination * advice given, including advice given if excluded or declines immunisation * details of any adverse drug reactions and actions taken * supplied via Patient Group Direction (PGD)   Records should be signed and dated (or a password controlled immunisers record on e-records).  All records should be clear, legible and contemporaneous.  This information should be recorded in the individual’s GP record. Where vaccine is administered outside the GP setting appropriate health records should be kept and the individual’s GP informed.  The local Child Health Information Systems team (Child Health Records Department) must be notified using the appropriate documentation/pathway as required by any local or contractual arrangement.  A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy. |

1. **Key references**

|  |  |
| --- | --- |
| **Key references** | **MMR vaccine**   * Immunisation Against Infectious Disease: The Green Book [Chapter 21](https://www.gov.uk/government/publications/measles-the-green-book-chapter-21), last updated 1 July 2013, [Chapter 23](https://www.gov.uk/government/publications/mumps-the-green-book-chapter-23), [Chapter 28](https://www.gov.uk/government/publications/rubella-the-green-book-chapter-28) and [Chapter 6](https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6) last updated 4 April 2013. <https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book> * Summary of Product Characteristic for MMRVaxPRO®, MSD Ltd. 19 June 2017.   <http://www.medicines.org.uk/emc/medicine/20968>   * Summary of Product Characteristic for Priorix®, GlaxoSmithKline. 2 November 2017.   <http://www.medicines.org.uk/emc/medicine/2054>   * NHS public health functions agreement 2017-18, Service Specification No.10. Measles mumps and rubella (MMR) immunisation programme. April 2017 <https://www.england.nhs.uk/publication/public-health-national-service-specifications/> * Revised recommendations for the administration of more than one live vaccine. Public Health England. 24 April 2015 <https://www.gov.uk/government/publications/revised-recommendations-for-administering-more-than-1-live-vaccine> * Guidelines on post-exposure prophylaxis for measles. Public Health England. August 2017.<https://www.gov.uk/government/publications/measles-post-exposure-prophylaxis>   **General**   * British National Formulary (BNF) and British National Formulary for Children (BNF-C) [www.BNF.org](http://www.BNF.org) <https://bnf.nice.org.uk/drug/measles-mumps-and-rubella-vaccine-live.html> * Health Technical Memorandum 07-01: Safe Management of Healthcare Waste. Department of Health 20 March 2013 <https://www.gov.uk/government/publications/guidance-on-the-safe-management-of-healthcare-waste> * Immunisation knowledge and skills competence assessment tool. Royal College of Nursing (RCN). <https://www.rcn.org.uk/professional-development/publications/pub-005336> * National Minimum Standards for Immunisation Training <https://www.gov.uk/government/publications/immunisation-training-national-minimum-standards> * NICE Medicines Practice Guideline 2 (MPG2): Patient Group Directions. Published March 2017. <https://www.nice.org.uk/guidance/mpg2> * NICE MPG2 Patient group directions: competency framework for health professionals using patient group directions. January 2014. <https://www.nice.org.uk/guidance/mpg2/resources> * PHE Immunisation Collection <https://www.gov.uk/government/collections/immunisation> * PHE Vaccine Incident Guidance   <https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors>   * Protocol for ordering storage and handling of vaccines. April 2014.   <https://www.gov.uk/government/publications/protocol-for-ordering-storing-and-handling-vaccines> |

1. **Practitioner authorisation sheet**

**MMR Vaccine PGD v02.00 Valid from: 01/03/2018 Expiry: 29/02/2020**

Before signing this PGD, check that the document has had the necessary authorisations in section two. Without these, this PGD is not lawfully valid.

**Practitioner**

By signing this patient group direction you are indicating that you agree to its contents and that you will work within it.

Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

|  |  |  |  |
| --- | --- | --- | --- |
| I confirm that I have read and understood the content of this Patient Group Direction and that I am willing and competent to work to it within my professional code of conduct. | | | |
| Name | Designation | Signature | Date |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**Authorising manager**

|  |  |  |  |
| --- | --- | --- | --- |
| I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of **INSERT NAME OF ORGANISATION** for the above named health care professionals who have signed the PGD to work under it. | | | |
| Name | Designation | Signature | Date |
|  |  |  |  |

**Note to authorising manager**

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.

1. This includes any relevant amendments to legislation (eg [2013 No.235](http://www.legislation.gov.uk/uksi/2013/235/contents/made), [2015 No.178](http://www.legislation.gov.uk/nisr/2015/178/contents/made) and [2015 No.323](http://www.legislation.gov.uk/uksi/2015/323/contents/made)). [↑](#footnote-ref-2)
2. Exclusion under this Patient Group Direction does not necessarily mean the medication is contraindicated, but it would be outside its remit and another form of authorisation will be required [↑](#footnote-ref-3)
3. Currently used live vaccines are BCG, rotavirus, live attenuated influenza vaccine (LAIV), oral typhoid vaccine, yellow fever, varicella, zoster and MMR [↑](#footnote-ref-4)